Predicting the future of anti-tumor necrosis factor therapy

Predicting the future of anti-tumor necrosis factor therapy

Tumor necrosis factor (TNF) antagonists are approved worldwide for the treatment of rheumatoid arthritis (RA). Clinical experience revealed that TNF-blocking therapy is effective for only approximately two thirds of patients, reflecting that there are 'responders' as well as 'nonresponders'. Given the destructive nature of RA, the risk of adverse effects, and considerable costs for therapy, the...

Tumor necrosis factor and anti-tumor necrosis factor therapies.

Tumor necrosis factor (TNF) plays a crucial role in the pathogenesis of immune-mediated inflammatory diseases (IMID). As a result, the inhibition of TNF is an important therapeutic avenue in the treatment of these pathophysiologically diverse disease states. This section discusses TNF, its receptors, and its role in immunoregulation and inflammation, as well as the currently available anti-TNF-...

Autoimmune Pitfalls of Anti-Tumor Necrosis Factor-Alpha Therapy.

Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.

3. Information on permissions/orders of reprints in rheumatology and related fields. Silverman featuring research articles on clinical subjects from scientists working is a monthly international serial edited by Earl D.

Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy

Patients receiving anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy are at increased risk for tuberculosis and other granulomatous diseases, but little is known about illness caused by nontuberculous mycobacteria (NTM) in this setting. We reviewed the US Food and Drug Administration MedWatch database for reports of NTM disease in patients receiving anti-TNF-alpha therapy. Of 239 report...